Forty-eight inbred Copenhagen rats 4-6 weeks old were injected in the subcutaneous layer of the right fl ank with 5 × 10⁵ MATLyLu cells, a rat prostate cancer cell line shown to produce local soft tissue tumors and metastatic lesions to the lymph nodes and lungs of male rats (Dunning model).⁴ Primary prostatic tumors were measured at the end of 2 weeks, when the rats were divided into four groups of 12 animals each with equal tumor size. Intraperitoneal injections were administered three times per week for 2 weeks, with Group 1 receiving [1,25(OH) 2 D 3 ] 100 ng, Group 2 receiving drug vehicle, Group 3 receiving a combination of [1,25(OH) 2 D 3 ] 100 ng plus pamidronate 1 mg, and Group 4 receiving only pamidronate 1 mg. At the end of 2 weeks, the tumors were excised; the primary tumor volume and the histopathological evidence of lung metastases were assessed. One lung slice/rat was examined. e pathologist did not know
Benefi cial eff ects of bisphosphonates on metastatic disease from prostate carcinoma have been reported.¹ In the Dunning rat prostate model system, 1 α, 25-dihydroxy vitamin D 3 [1, 25(OH) 2 D 3 ] has also shown effi cacy in inhibiting the primary tumor volume and in reducing the number and size of lung metastases.² However, concerns about inducing hypercalcemia and hypercalciuria in cancer patients have limited the use of [1, 25(OH) 2 At the end of 2 weeks, the tumors were excised; the primary tumor volume and the histopathological evidence of lung metastases were assessed. One lung slice/rat was examined. e pathologist did not know the source of the lung examined. Laboratory studies included serum BUN, creatinine, aspartate transaminase (AST), alanine transaminase (ALT), calcium, and cytokine levels (interleukin 6, interleukin 1 beta, and interferon gamma).
An additional 30 inbred Copenhagen rats 4-6 weeks old were used to determine the eff ect of treatment on survival. ey were divided into four groups, which were given intraperitoneal injections three times per week for 2 weeks and treated in the same way as the experimental groups: Group 1 received [ Rats in this study were sacrifi ced when any signs of respiratory distress were present. All studies were conducted in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals.
All statistics except the survival analysis were done using analysis of variance (). To determine the eff ects of treatment arm on overall survival, a time to event analysis was used. All statistics were done using the SAS System for Windows (version 8.1).
e biochemical results are summarized in Table  1 . ere were no diff erences among the groups with respect to serum creatinine, AST, ALT, and BUN. On the other hand, calcium levels were higher in Group Creatinine 0.7 ± 0.2 (n = 9) 0.6 ± 0.1 (n = 9) 0.6 ± 0.1 (n = 9) 0.6 ± 0.1 (n = 10) 0.49 AST 274.3 ± 146.1 (n = 8) 215.2 ± 84.6 (n = 9) 242.4 ± 117.0 (n = 9) 187.2 ± 57.6 (n = 10) 0.35 ALT 38.9 ± 27.8 (n = 8) 33.1 ± 13.4 (n = 9) 40.8 ± 31.8 (n = 9) 26.2 ± 6.5 (n = 10) 0.48 BUN 25.4 ± 17.0 (n = 9) 32.0 ± 18.9 (n = 9) 48.6 ± 44.6 (n = 9) 23.1 ± 8.8 (n = 10) 0.16 Calcium 11.0 ± 1.1 (n = 9) 10.6 ± 1.0 (n = 9) 9.6 ± 0.5 (n = 9) 9.7 ± 0.2 (n = 10) 0.0004
Interleukin 6 788.4 ± 72.1 (n = 9) 892.9 ± 83.1 (n = 10) 1803.0 ± 1259.2 (n = 8) 899.6 ± 23.6 (n = 9) 0.004
Interleukin 1B 142.1 ± 207.7 (n = 9) 169.5 ± 164.1 (n = 10) 89.6 ± 111.4 (n = 8) 75.8 ± 66.1 (n = 9) 0.50
Interferon gamma 18.8 ± 7.2 (n = 9) 17.2 ± 4.4 (n = 10) 26.9 ± 4.8 (n = 8) 70.3 ± 74.7 (n = 9) 0.02 dronate 1 mg) and Group 4 (pamidronate 1 mg) (p = 0.0004 and p = 0.0005, respectively). e calcium levels of Group 2 were also statistically signifi cantly higher than Group 3 (p = 0.0075) and Group 4 (p = 0.0095).
Interleukin 6 and interferon gamma levels diff ered signifi cantly among the treatment groups, with interleukin 6 levels higher in Group 3 (combination of 1,25-dihydroxy vitamin D³ 100 ng and pamidronate 1 mg) relative to all other groups (p = 0.0013 vs. Group 1, p = 0.0028 vs. Group 2, and p = 0.0036 vs. group 4), and interferon gamma levels higher in Group 4 (pamidronate 1 mg) relative to all other groups (p = 0.01 versus Group 1, p = 0.004 vs. Group 2, and p = 0.02 vs. Group 3).
Interleukin 1 beta levels did not diff er among the groups (p > 0.05).
Pathological fi ndings: ere were no diff erences among the groups with respect to the primary prostatic tumor weight (p > 0.05), the presence or absence of metastatic lesions to the lungs (p > 0.05), or the absolute number of metastatic lung lesions (p > 0.05), although the number of rats with metastatic lung lesions as well as the absolute number of metastatic lesion was small (n = 11 and n = 35, respectively). In addition, there was no eff ect of treatment group on overall survival time.
In our study, there was upregulation of interferon gamma levels, a cytokine, which has been associated with antitumor responses⁴ in the group treated with pamidronate alone. In contrast, the group treated with the combination of pamidronate with [1,25(OH)₂D₃] had increased levels of interleukin 6, a cytokine that has been associated with tumor promotion.⁵ Despite these diff erences in cytokine profi les among the groups, we found no eff ect of therapy with [1,25(OH)₂D₃], pamidronate, or the combination of [1,25(OH)₂D₃] with pamidronate at reducing the primary prostatic tumor burden and metastatic lung disease, or improving the overall survival in the Dunning rat model. e combination of pamidronate with vitamin D at the doses used in our study is not eff ective at ameliorating prostate cancer in the Dunning rat model. In contrast, monotherapy with pamidronate was associated with potentially favorable eff ects on the cytokine profi les in this model and merits further study.
